tbuckley/cabot-search huggingface dataset:
Changes in Hospital–Physician Affiliations in U.S. Hospitals
Authors: Edward Ringel
Journal: Annals of Internal Medicine (2018)

Letters16 January 2018Changes in Hospital–Physician Affiliations in U.S. HospitalsEdward Ringel, MDEdward Ringel, MDMaineGeneral Medical Center, Augusta, Maine (E.R.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0683 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I read Scott and colleagues' article (1) with interest. Between October 2008 and August 2016, I functioned in a position akin to chief medical information officer at a midsized rural hospital. We rapidly acquired practices during that period, largely because of the increasing administrative burden of private practice and the economics of rural practice in central Maine. I had substantial responsibility for integrating practices into our EHR and enhancing its function. We used our EHR as a means of driving and standardizing care among our current employees. Thus, I was in a position to observe the evolution ...Reference1. Scott KW, Orav EJ, Cutler DM, Jha AK. Changes in hospital–physician affiliations in U.S. hospitals and their effect on quality of care. Ann Intern Med. 2017;166:1-8. [PMID: 27654704]. doi:10.7326/M16-0125 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: MaineGeneral Medical Center, Augusta, Maine (E.R.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0683. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoChanges in Hospital–Physician Affiliations in U.S. Hospitals and Their Effect on Quality of Care Kirstin W. Scott , E. John Orav , David M. Cutler , and Ashish K. Jha Changes in Hospital–Physician Affiliations in U.S. Hospitals Russell L. Bedsole Changes in Hospital–Physician Affiliations in U.S. Hospitals Alan R. Ertle Changes in Hospital–Physician Affiliations in U.S. Hospitals Kirstin W. Scott , E. John Orav , David M. Cutler , and Ashish K. Jha Metrics 16 January 2018Volume 168, Issue 2Page: 156KeywordsBehaviorConflicts of interestDisclosureHealth care qualityInformation storage and retrievalInformation technologyMotivationRunningShock ePublished: 16 January 2018 Issue Published: 16 January 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract 18891: Importance of Sodium Level Trajectory in Acute Heart Failure
Authors: Kenji Yoshioka, Yuya Matsue, Makoto Suzuki, Sho Torii, Satoshi Yamaguchi, Seiji Fukamizu, Yuichi Ono, Hiroyuki Fujii, Takeshi Kitai, Toshihiko Nishioka, Kaoru Sugi, Yuko Onishi, Makoto Noda, Nobuyuki Kagiyama, Yasuhiro Satoh, Kazuki Yoshida, Steven R Goldsmith
Journal: Circulation (2016)

Background: Hyponatremia is a common electrolyte disorder which is strongly associated with poor prognosis in acute heart failure (AHF); however, the prognostic impact of the sodium level trajectory has not been determined. Methods: A secondary analysis of the AQUAMARINE study in which patients with AHF and renal impairment (eGFR < 60 mL/min/1.73 m2) were randomized to receive either tolvaptan or conventional treatment was performed. Sodium levels were evaluated at baseline, 6, 12, 24, and 48 hours after randomization. We defined ‘sodium dipping’ as sodium level falling below the baseline level at any timepoint. All patients were categorized into a dipping or non-dipping group. The primary endpoint was the combined event of all-cause death and heart failure rehospitalization. Results: The analysis included 184 patients with a median follow-up of 21.1 months. Sodium levels more steeply increased during the 48 hours in patients without events as compared to sodium levels in patients with events (P=0.033). T...
Abstract 16601: APD811, a Novel and Highly Selective Non-prostanoid IP Receptor Agonist in Smooth Muscle Cells From Patients With Pulmonary Hypertension
Authors: Lei Shen, Jigisha Patel, Dominic Behan, John Adams, Lucie Clapp
Journal: Circulation (2016)

Introduction: APD811 is an oral, non-prostanoid IP receptor agonist with a long plasma half-life (~ 24 hr) in development by Arena Pharmaceuticals Inc for pulmonary arterial hypertension (PAH). Lit...
PTH-107 The impact of inflammatory bowel disease on the body composition of adults and adolescents
Authors: K Keetarut, G Grimble, D Hajjar
Journal: Gut (2017)

Introduction  Inflammatory bowel disease (IBD) is a chronic condition which comprises of Crohn’s Disease (CD) and Ulcerative Colitis (UC). Significant abnormalities in body composition including muscle mass depletion have been found in IBD patients despite a healthy Body mass index (BMI) (Valentini et al, 2008). The purpose of this study was to compare the effects of IBD, both CD, and UC on the body composition of adults and adolescents.  Method  A pilot prospective study was conducted over 6 weeks. Patients with a confirmed diagnosis of IBD were recruited through convenience sampling in the adolescent and adult outpatient clinic.  Information was collected via questionnaire on patient demographics and nutritional status including body mass index (BMI), waist circumference (WC), Mid Upper Arm Circumference (MUAC), pinch strength, grip strength and body fat composition using the Bioelectrical impedence analysis (BIA) and tricep Skinfold thickness (TSF).  Results  27 participants were recruited (15 adults and 12 adolescents) average age 32 (range 14–55), 14 were female only one was a smoker. In adults with CD and UC there was no statistical difference respectively in BMI score (24.8 versus 26.2) WC, MUAC, pinch strength, grip strength, BIA and TSF. There was a statistically significant difference between adults and adolescents with CD respectively for BMI (24.8 versus 19.7), WC (87.4 versus 72.6), MUAC (29.6 versus 24.4), pinch (8.3 versus 3.5) and grip strength (29.4 versus 13.7) but no statistical difference for TSF (33.4 versus 33.2) and BIA (24.8 versus 22.3).  There was no statistically significant difference in BMI (19.7 versus 25.9), WC (72.6 versus 75.2), TSF (33.2 versus 31.5) or BIA (25.0 versus 25.6). There was a statistical significant difference in MUAC (24.4 versus 32.4), pinch (3.5 versus 5.2) and grip strength (13.7 versus 25.7) but no statistical difference for TSF (33.4 versus 33.2) and BIA (24.8 versus 22.3).  Conclusion  When comparing CD and UC in adolescents, UC had less adverse outcomes on body composition and muscle function. CD adversely affects the body composition and muscle function of adolescents more than adults. Understanding how each form of IBD affects people of various ages is critical in the management of IBD. Improvements are required to complete more thorough nutritional assessments and further dietetic input is required to manage those at highest nutritional risk including adolescent CD patients.  References  . Hill, R (2014). Update on nutritional status, body composition and growth in paediatric inflammatory bowel disease.  . Bryant R, Trott M, Bartholemeusz F, et al.Systematic review: body composition in adults with inflammatory bowel disease. Aliment Pharamcol Ther. 2013; 38:213–225.  Disclosure of Interest  None Declared
Erratum: Corrigendum: Mutations in smooth muscle α-actin (ACTA2) lead to thoracic aortic aneurysms and dissections
Authors: Dong-Chuan Guo, Hariyadarshi Pannu, Van Tran-Fadulu, Christina L Papke, Robert K Yu, Nili Avidan, Scott Bourgeois, Anthony L Estrera, Hazim J Safi, Elizabeth Sparks, David Amor, Lesley Ades, Vivienne McConnell, Colin E Willoughby, Dianne Abuelo, Marcia Willing, Richard A Lewis, Dong H Kim, Steve Scherer, Poyee P Tung, Chul Ahn, L Maximilian Buja, C S Raman, Sanjay S Shete, Dianna M Milewicz
Journal: Nature Genetics (2008)
Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity
Authors: Yuli Cai, Honggui Li, Mengyang Liu, Ya Pei, Juan Zheng, Jing Zhou, Xianjun Luo, Wenya Huang, Linqiang Ma, Qiuhua Yang, Shaodong Guo, Xiaoqiu Xiao, Qifu Li, Tianshu Zeng, Fanyin Meng, Heather Francis, Shannon Glaser, Lulu Chen, Yuqing Huo, Gianfranco Alpini, Chaodong Wu
Journal: Hepatology (2018)

Adenosine 2A receptor (A2AR) exerts protective roles in endotoxin‐ and/or ischemia‐induced tissue damage. However, the role for A2AR in nonalcoholic fatty liver disease (NAFLD) remains largely unknown. We sought to examine the effects of global and/or myeloid cell‐specific A2AR disruption on the aspects of obesity‐associated NAFLD and to elucidate the underlying mechanisms. Global and/or myeloid cell–specific A2AR‐disrupted mice and control mice were fed a high‐fat diet (HFD) to induce NAFLD. In addition, bone marrow–derived macrophages and primary mouse hepatocytes were examined for inflammatory and metabolic responses. Upon feeding an HFD, both global A2AR‐disrupted mice and myeloid cell–specific A2AR‐defcient mice revealed increased severity of HFD‐induced hepatic steatosis and inflammation compared with their respective control mice. In in vitro experiments, A2AR‐deficient macrophages exhibited increased proinflammatory responses, and enhanced fat deposition of wild‐type primary hepatocytes in macrophage–hepatocyte cocultures. In primary hepatocytes, A2AR deficiency increased the proinflammatory responses and enhanced the effect of palmitate on stimulating fat deposition. Moreover, A2AR deficiency significantly increased the abundance of sterol regulatory element‐binding protein 1c (SREBP1c) in livers of fasted mice and in hepatocytes upon nutrient deprivation. In the absence of A2AR, SREBP1c transcription activity was significantly increased in mouse hepatocytes. Conclusion: Taken together, our results demonstrate that disruption of A2AR in both macrophage and hepatocytes accounts for increased severity of NAFLD, likely through increasing inflammation and through elevating lipogenic events due to stimulation of SREBP1c expression and transcription activity. (Hepatology 2018;68:48‐61).
An optimal window of age for epicutaneous sensitization following tape-stripping in mice
Authors: Masato Tamari, Keisuke Orimo, Kenichiro Motomura, Ken Arae, Susumu Nakae, Akio Matsuda, Hideaki Morita, Hirohisa Saito, Kenji Matsumoto
Journal: Journal of Allergy and Clinical Immunology (2018)
Treatment of acute hepatitis C virus is cost‐effective but at what price?
Authors: Stephen E. Congly, Samuel S. Lee
Journal: Hepatology (2018)

Potential conflict of interest: Nothing to report. TO THE EDITOR: Bethea et al.1 provide an interesting study modeling that early treatment of acute hepatitis C virus (HCV) is cost‐effective and potentially cost‐saving in a group at high risk of transmission rather than waiting until chronicity is confirmed in 6 months' time. Current American Association for the Study of Liver Diseases guidelines2 recommend against treating acute HCV given a spontaneous clearance rate of approximately 28%.3 Acute HCV is largely asymptomatic, so identified cases will typically have symptoms, particularly jaundice; spontaneous clearance may approach 50% in patients with jaundice.4 Initial data suggest that shorter treatment courses are efficacious for acute HCV, although the trials are small and only genotype 1 was studied. The reduced length of treatment is the key determinant of the differences between the strategies cost‐wise in this model; as more patients spontaneously clear, the cost‐effectiveness of treating acute HCV decreases. Although this study suggests that early treatment is cost‐effective in patients at low risk of transmission and cost‐saving for patients at high risk of transmission, implementing an acute treatment strategy carries the risk of significant unnecessary costs for patients who would otherwise spontaneously clear the infection. Assuming a spontaneous clearance rate of 28% and 34,000 acute HCV infections in the United States annually, 9,520 people would receive potentially unneeded therapy. As such, between $4,598,160 and $79,225,440 (2016 USD) of unnecessary spending would be required depending on whether acute HCV required 6 or 8 weeks of treatment versus 8 weeks for chronic HCV. For patients at high risk of transmission, if both strategies require an 8‐week treatment duration, there could be an additional cost of $27,398,560, while if acute HCV could be treated with a shorter duration, early treatment would be cost‐saving due to the reduced risk of transmission. The authors provide important data for policy makers and clinicians to consider; however, we would caution against any major changes for patients at low risk of transmission until further data on the efficacy of direct‐acting antiviral agents are available for all genotypes given the significant expense for patients who would spontaneously clear. For patients at high risk of transmission, the added cost of treating individuals who would otherwise spontaneously clear may be of value given reduced transmission rates if acute HCV requires similar treatment duration to chronic HCV. If a shorter duration is possible, early treatment of high‐risk patients with acute HCV would be good public health policy given that it is cost‐saving.
Smartphone GP consultation app cost CCG £150 000 in first two months
Authors: Gareth Iacobucci
Journal: BMJ (2018)

High demand for a new service that allows patients to access GP consultations 24 hours a day on their smartphones is leading to increased hospital activity, NHS bosses have reported.

The GP at Hand service, launched by the Lillie Road Surgery in Hammersmith, west London, and the digital health company Babylon Health, has been marketed across London since it launched in November 2017.12 The practice more than trebled its patient list in the first two months of the new service, from 4970 on 1 November to 16 117 on 1 January.3 More than 90% (10 051) of the 11 147 new patients were aged between 20 and 44 years old. Under NHS regulations people who live outside …
Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer
Authors: Tamara Muliaditan, James W. Opzoomer, Jonathan Caron, Mary Okesola, Paris Kosti, Sharanpreet Lall, Mieke Van Hemelrijck, Francesco Dazzi, Andrew Tutt, Anita Grigoriadis, Cheryl E. Gillett, Stephen F. Madden, Joy M. Burchell, Shahram Kordasti, Sandra S. Diebold, James F. Spicer, James N. Arnold
Journal: Clinical Cancer Research (2018)

Purpose: Unprecedented clinical outcomes have been achieved in a variety of cancers by targeting immune checkpoint molecules. This preclinical study investigates heme oxygenase-1 (HO-1), an immunosuppressive enzyme that is expressed in a wide variety of cancers, as a potential immune checkpoint target in the context of a chemotherapy-elicited antitumor immune response. We evaluate repurposing tin mesoporphyrin (SnMP), which has demonstrated safety and efficacy targeting hepatic HO in the clinic for the treatment of hyperbilirubinemia, as an immune checkpoint blockade therapy for the treatment of cancer.Experimental Design: SnMP and genetic inactivation of myeloid HO-1 were evaluated alongside 5-fluorouracil in an aggressive spontaneous murine model of breast cancer (MMTV-PyMT). Single-cell RNA sequencing analysis, tumor microarray, and clinical survival data from breast cancer patients were used to support the clinical relevance of our observations.Results: We demonstrate that SnMP inhibits immune suppression of chemotherapy-elicited CD8+ T cells by targeting myeloid HO-1 activity in the tumor microenvironment. Microarray and survival data from breast cancer patients reveal that HO-1 is a poor prognostic factor in patients receiving chemotherapy. Single-cell RNA-sequencing analysis suggests that the myeloid lineage is a significant source of HO-1 expression, and is co-expressed with the immune checkpoints PD-L1/2 in human breast tumors. In vivo, we therapeutically compare the efficacy of targeting these two pathways alongside immune-stimulating chemotherapy, and demonstrate that the efficacy of SnMP compares favorably with PD-1 blockade in preclinical models.Conclusions: SnMP could represent a novel immune checkpoint therapy, which may improve the immunological response to chemotherapy. Clin Cancer Res; 24(7); 1617-28. ©2018 AACR.
Hysterectomy to Treat Pain in a Teen With Severe Physical and Intellectual Disabilities: Responding to a Mother's Request
Authors: Jeffrey P. Spike
Journal: The American Journal of Bioethics (2018)

"Hysterectomy to Treat Pain in a Teen With Severe Physical and Intellectual Disabilities: Responding to a Mother's Request." The American Journal of Bioethics, 18(1), pp. 65–66
Early Detection of Subclinical Myocardial Damage in Chronic Aortic Regurgitation and Strategies for Timely Treatment of Asymptomatic Patients
Authors: Joe K.T. Lee, Anna Franzone, Jonas Lanz, George C.M. Siontis, Stefan Stortecky, Christoph Gräni, Eva Roost, Stephan Windecker, Thomas Pilgrim
Journal: Circulation (2018)

A series of hemodynamic and pathological responses occur in chronic aortic regurgitation, which eventually result in myocardial fibrosis and irreversible left ventricular dysfunction. According to guidelines, valvular surgery is recommended with the development of symptoms, left ventricular systolic dysfunction, or left ventricular dilatation. The optimal timing of surgical intervention has recently been questioned with documentation of irreversible myocardial damage resulting in incomplete left ventricular recovery and adverse clinical outcomes after surgery. Recognizing the shortcomings of the guidelines, we performed a comprehensive review on the novel diagnostic methods that have been shown to improve the detection of subclinical ventricular dysfunction in chronic aortic regurgitation and to improve prediction of outcomes.
The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding
Authors: Liam B. King, Marnie L. Fusco, Andrew I. Flyak, Philipp A. Ilinykh, Kai Huang, Bronwyn Gunn, Robert N. Kirchdoerfer, Kathryn M. Hastie, Amandeep K. Sangha, Jens Meiler, Galit Alter, Alexander Bukreyev, James E. Crowe, Erica Ollmann Saphire
Journal: Cell Host & Microbe (2018)
Abstract 17315: Specific and Increased Expression of Thrombin Receptor PAR1 in Pulmonary Artery Plays a Key Role in the Pathogenesis of Monocrotaline-induced Pulmonary Hypertension in Rats
Authors: Yukimitsu Kuwabara, Mariko Tanaka, Kohtaro Abe, Mayumi Hirano, Yoshitaka Hirooka, Kenji Sunagawa, Katsuya Hirano
Journal: Circulation (2016)

Background: The prognosis of pulmonary arterial hypertension (PAH) still remains poor. Identification of therapeutic targets that play not only a key role but also a specific role in the pathogenes...
Erratum. Factors Associated With Diabetes-Specific Health-Related Quality of Life in Youth With Type 1 Diabetes: The Global TEENs Study. Diabetes Care 2017;40:1002—1009
Authors: Barbara J. Anderson, Lori M. Laffel, Catherine Domenger, Thomas Danne, Moshe Phillip, Carmen Mazza, Ragnar Hanas, Sheridan Waldron, Roy W. Beck, Francoise Calvi-Gries, Chantal Mathieu
Journal: Diabetes Care (2018)

In the article cited above, the Supplementary Data file for the “TEENs—List of Contributors” was …
Response to: ‘Performance of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice’ by Hočevar <i>et al</i>
Authors: Ingrid E Lundberg, Matteo Bottai, Anna Tjärnlund
Journal: Annals of the Rheumatic Diseases (2018)

We read with interest the letter titled ‘Performance of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice’ by Hocevar et al published in the Annals of the Rheumatic Diseases .1 In the letter the authors report the sensitivity and specificity of the recently published ‘ 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups ’2 observed in a retrospective cohort of 95 patients with idiopathic inflammatory myopathies (IIM) collected between 2010 and 2017 in a Slovenian rheumatology centre. As comparators, they used 72 subjects who had had a work-up for …
Prospective Validation of an Algorithm for the Evaluation and Treatment of Hypersensitivity Reactions to Taxanes, Including Desensitizations
Authors: Teodorikez W. Jimenez Rodriguez, Leticia de las Vecillas Sánchez, Marlene Garcia-Neuer, Cintia A. Falck-Fuentes, Donna-Marie Lynch, Kathleen A. Marquis, Leila A. Alenazy, Mariana C. Castells
Journal: Journal of Allergy and Clinical Immunology (2018)
Liquid Biopsy for the Identification of Intravascular Large B-Cell Lymphoma
Authors: Yasuhito Suehara, Mamiko Sakata-Yanagimoto, Keiichiro Hattori, Yoshiaki Abe, Kentaro Narita, Masami Takeuchi, Kosei Matsue, Takayoshi Itoh, Daisuke Kaji, Go Yamamoto, Toru Nanmoku, Naoko Baba, Manabu Kusakabe, Tatsuhiro Sakamoto, Naoki Kurita, Yasuhisa Yokoyama, Hidekazu Nishikii, Yuichi Hasegawa, Naoshi Obara, Shigeru Chiba
Journal: Blood (2017)
Image Gallery: Acquired palmoplantar keratoderma due to hypothyroidism
Authors: J.C. Prezzano, S.C. Reddy, F.A. Tausk
Journal: British Journal of Dermatology (2017)

Funding sources: none. Conflicts of interest: none declared. Dear Editor, A 67‐year‐old woman with a long history of rheumatoid arthritis presented to the dermatology clinic with two years of progressive palmoplantar keratoderma predominantly affecting her soles, with minimal involvement of the palms. Her care had been neglected. Treatment with topical keratolytics and steroids was unsuccessful. Laboratory testing revealed profound hypothyroidism (thyroid‐stimulating hormone 238 μIU mL−1). Malignancy work‐up was unrevealing. Correction of her underlying hypothyroidism with levothyroxine resulted in rapid improvement of her palmoplantar keratoderma with complete resolution in 4 months. The pathogenesis of palmoplantar keratoderma associated with hypothyroidism is poorly understood. Reports suggest dysregulation of the intracellular stratum corneum lipids, although supporting evidence for this connection is poor.1,2
Neuronal IL-4Rα and JAK1 signaling critically mediate atopic dermatitis-associated
Authors: Landon K. Oetjen, Madison R. Mack, Jing Feng, Timothy M. Whelan, Haixia Niu, Changxiong J. Guo, Sisi Chen, Anna M. Trier, Amy Z. Xu, Shivani V. Tripathi, Jialie Luo, Xiaofei Gao, Lihua Yang, Samantha L. Hamilton, Peter L. Wang, Jonathan R. Brestoff, Martha L. Council, Richard Brasington, Andras Schaffer, Frank Brombacher, Chyi-Song Hsieh, Robert W. Gereau, Mark J. Miller, Zhou-Feng Chen, Hongzhen Hu, Steve Davidson, Qin Liu, Brian S. Kim
Journal: Journal of Allergy and Clinical Immunology (2018)